WAR 2 5 TRADE HARTS

<110>

SEQUENCE LISTING

```
<110> Abbott Laboratories
Henkin, Jack
Haviv, Fortuna
Bradley, Michael F.
Kalvin, Douglas M.
Schneider, Andrew J.
```

<120> PEPTIDE ANTIANGIOGENIC DRUGS

```
<130> 6356.US.P3
```

<140> 09/447,226

<141> 1999-11-22

<150> US 09/316,888

<151> 1999-05-21

<150> US 60/126,546

<151> 1999-03-26

<150> US 60/086,536

<151> 1998-05-22

<160> 6

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Antiangiogenetic Peptide

<221> VARIANT

<222> (1)...(1)

<223> Xaa = Ala, Asn, Cit, Gln, Glu, NEtGly, Met, N-methyladanyl, Pro, pyro-Glu, Sar, Ser, or Thr at position 1

<221> VARIANT

<222> (2) . . . **/**2)

<223> Xaa = Ala, Asn, Asp, Gln, Glu, Leu, Met, Phe, Pro,
or Set at position 2

<221> VARIANT

<222> (3) ...(3)

<223> Xaa = Ala, Asn, Cit, Cha, Chg, Gln, Glu, Gly, Ile, Let, Met, Nva, Phe, Ser, tButylgly, Thr, Val, Pen, or Cys at position 3

<221> VARIANT

```
<222> (4)...(4)
<223> Xaa = alloIle, Gly, Ile, Pro, or dehydroleu at
      position 4
<221> VARIANT
<222> (5)...(5)
<223> Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-thrgonyl,
      allylgly, Gln, Gly, His, Hser, Ile, Lys/Ac), Met,
      Nva, Octylgly, Orn, Phe(4-CH2OH), Pro,/Ser, Thr,
      Trp, Tyr, Pen, or Cys at position 5
<221> VARIANT
<222> (6)...(6)
<223> Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly,
      Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His,
      Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp),
      at position 6
<221> VARIANT
<222> (6)...(6)
<223> 6 Cont'd:
      Xaa = Met(O2), Met(O), Met, Nor, Nva, Octygly,
      Phe, Phe(4-CONH2), Propargylgly, Ser, Thr, Trp,
      Tyr, Val, Pen, or Cys a \not t position 6
<221> VARIANT
<222> (7)...(7)
<223> Xaa = Ala, Allylgly Asn, Cit, Chg, Gln, Gly,
      Hser, Ile, alloIle Leu, Lys(Ac), Met, 1-Nal,
      2-Nal, Nva, Phe, Pro, Ser, tButylgly, Trp, Tyr,
      Val, Pen, or Cys at position 7
<221> VARIANT
<222> (8)...(8)
<223> Xaa = Aminopyp imidinobutanoyl, Ala(3-guanidino),
      Ala(3-pyrrolidinylamidino), Ala[4-Pip(N-amidino)],
      Arg, arginyl(MGNG'diethyl), Cit, Cha(4-NIsp),
      Gly[4-pip(N-amido)], at position 8
<221> VARIANT
<222> (8)...(8)
<223> 8 Cont'd:
      Xaa = His, Harg, Lys, Lys(Ile), Lys(Nic), Norarg,
Orn(Isp), Orn(Nic), Orn(2-imidazo),
      Phe(4-CH2NHIsp), Phe(4-guanidino), or Phe(4-NIsp)
      at posit on 8
<221> VARIANT
<222> (9)...(9)
<223> Xaa = /Abu, Aib, homoprolyl, hydroxyprolyl, Ile,
      Leu, Phe, Pro, Ser, tButylgly, Tic, Thr, or Val at
      position 9
<221> VARTANT
<222> (1/0) ... (10)
<223> Xa = azaglycylamide, glycylamide,
      alycylethylamide, sarcosylamide, serylamide at
```

```
position 10
<400> 1
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1
                 5
<210> 2
<211> 9
<212> PRT
<213> Artificial Sequence
<223> Antiangiogeneti¢ peptide
<221> VARIANT
<222> (1)...(1)
<223> Xaa = sarcosyl at position 1
<221> VARIANT
<222> (6)...(6)
<223> Xaa = nor valine at position 6
<400> 2
Xaa Gly Val I e Thr Xaa Ile Arg Pro
<210> 3
<211> 9
<212> PRT
<213> Art ficial Sequence
<223> Artiangiogenetic peptide
<221> VARIANT
<222> /(1) ... (1)
<223> Xaa = sarcosyl at position 1
<221 VARIANT
<222 (6)...(6)
<223> Xaa = norvaline at position 6
<400> 3
Xaa Gly Val Gly Thr Xaa Ile Arg Pro
 210> 4
k211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Antiangiogenetic peptide
```

```
<221> VARIANT
<222> (1) ...(1)
\langle 223 \rangle Xa =  sarcosyl at position 1
<221> VARIANT
<222> (4).\((4))
<223> Xaa = \allo-isoleucyl at position 4
<221> VARIANT
<222> (6)...(6)
<223> Xaa = norvaline at position 6
<400> 4
Xaa Gly Val Xaa Thr Xaa Ile Arg Pro
<210> 5
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Antiangiogenetic peptide
<221> VARIANT
<222> (1)...(1)
<223> Xaa = sarcosyl at position 1
<221> VARIANT
<222> (4)...(4)
<223> Xaa = dehydroleucyl at position 4
<221> VARIANT
<222> (6)...(6)
<223> Xaa = norvaline at position 6
<400> 5
Xaa Gly Val Xaa Thr Xaa Ile Arg Pro
<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> Antiangiogenetic Peptide
<221> VARIANT
<222> (1)...(1)
<223> Xaa = R-(CH2)n-C(O) - where R \frac{1}{4}s N-acetylamino at
      position 1
<221> VARIANT
<222> (2)...(2)
```

```
<223> Xaa = Sar\at position 2
<221> VARIANT
<222> (5)...(5)
<223> Xaa = AlloIIe, dehydroleu, Gly, Ile or Pro at
       position 5
<221> VARIANT
<222> (6)...(6)
\langle 223 \rangle Xaa = Ala, 3-Pal\ 1-Nal, 2-Nal, allo-threonyl,
       allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met,
       Nva, Octylgly, Orn, Phe(3-CH2OH), Pro, Ser, Thr,
       Trp, Tyr, Pen or Cys at position 6
<221> VARIANT
<222> (7)...(7)
<223> Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly,
Arg, Asn, Asp, Cit, tha, Gln, Glu, Gly, His,
Homoala, Hle, Hser, le, Leu, Lys(Ac), Lys(Isp),
       at position 7
<221> VARIANT
<222> (7)...(7)
<223> 7 Con'td:
       Xaa = Met(O2), Met(O), Met, Nor, Nva, Octygly,
       Phe, Phe(4-CONH2), Proparglygly, Ser, Thr, Trp, Tyr, Val, Pen, or Cys at position 7
<221> VARIANT
<222> (11)...(11)
<223> Xaa = Azaglycylamide, glycylamide,
       glycylethylamide, sarcosylamide, serylamide at
       position 11
<400> 6
Xaa Xaa Gly Val Xaa Xaa Xaa Ile Arg Rro Xaa
```